PL3224254T3 - Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków - Google Patents

Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków

Info

Publication number
PL3224254T3
PL3224254T3 PL15800828T PL15800828T PL3224254T3 PL 3224254 T3 PL3224254 T3 PL 3224254T3 PL 15800828 T PL15800828 T PL 15800828T PL 15800828 T PL15800828 T PL 15800828T PL 3224254 T3 PL3224254 T3 PL 3224254T3
Authority
PL
Poland
Prior art keywords
preparation
medicaments
pharmaceutical formulations
formulations containing
substituted indazoles
Prior art date
Application number
PL15800828T
Other languages
English (en)
Inventor
Ulrich Bothe
Holger Siebeneicher
Nicole Schmidt
Reinhard Nubbemeyer
Ulf Bömer
Judith GÜNTHER
Holger STEUBER
Martin Lange
Christian Stegmann
Andreas Sutter
Alexandra RAUSCH
Peter Hauff
Christian Friedrich
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of PL3224254T3 publication Critical patent/PL3224254T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL15800828T 2014-11-26 2015-11-25 Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków PL3224254T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14195032 2014-11-26
PCT/EP2015/077596 WO2016083433A1 (de) 2014-11-26 2015-11-25 Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
EP15800828.4A EP3224254B1 (de) 2014-11-26 2015-11-25 Substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number Publication Date
PL3224254T3 true PL3224254T3 (pl) 2020-09-21

Family

ID=51982455

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19191936.4T PL3674298T3 (pl) 2014-11-26 2015-11-25 Nowe podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków
PL15800828T PL3224254T3 (pl) 2014-11-26 2015-11-25 Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19191936.4T PL3674298T3 (pl) 2014-11-26 2015-11-25 Nowe podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków

Country Status (42)

Country Link
US (6) US10308634B2 (pl)
EP (3) EP3674298B9 (pl)
JP (1) JP6496823B2 (pl)
KR (1) KR102083857B1 (pl)
CN (2) CN110305109B (pl)
AR (1) AR102827A1 (pl)
AU (2) AU2015352603B2 (pl)
BR (2) BR112017011005B1 (pl)
CA (1) CA2968614C (pl)
CL (1) CL2017001364A1 (pl)
CO (1) CO2017005374A2 (pl)
CR (1) CR20170220A (pl)
CU (1) CU24448B1 (pl)
CY (1) CY1123815T1 (pl)
DK (2) DK3224254T3 (pl)
DO (1) DOP2017000127A (pl)
EA (1) EA032509B1 (pl)
EC (1) ECSP17032530A (pl)
ES (2) ES2796285T3 (pl)
FI (1) FI3674298T3 (pl)
HR (2) HRP20240414T1 (pl)
HU (2) HUE065938T2 (pl)
IL (3) IL252185B (pl)
JO (1) JO3705B1 (pl)
LT (2) LT3224254T (pl)
MA (1) MA41011B1 (pl)
ME (1) ME03745B (pl)
MX (2) MX380150B (pl)
NI (1) NI201700063A (pl)
NZ (1) NZ732126A (pl)
PE (1) PE20171376A1 (pl)
PH (1) PH12017500972A1 (pl)
PL (2) PL3674298T3 (pl)
PT (2) PT3224254T (pl)
RS (2) RS60284B1 (pl)
SG (3) SG10201903474PA (pl)
SI (2) SI3224254T1 (pl)
TN (1) TN2017000226A1 (pl)
TW (2) TWI717061B (pl)
UA (2) UA123813C2 (pl)
UY (1) UY36411A (pl)
WO (1) WO2016083433A1 (pl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10160753B2 (en) 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
PT3466955T (pt) 2014-01-13 2021-01-29 Aurigene Discovery Tech Ltd Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3195865A1 (de) * 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
TW201701879A (zh) * 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
EA035867B1 (ru) * 2016-04-29 2020-08-24 Байер Фарма Акциенгезельшафт Синтез индазолов
HUE049331T2 (hu) * 2016-04-29 2020-09-28 Bayer Pharma AG Indazolok szintézise
CN109071489B (zh) 2016-04-29 2020-07-10 拜耳医药股份有限公司 吲唑的合成
AU2017273771B2 (en) * 2016-06-01 2022-09-29 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
RU2743170C2 (ru) * 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
TWI771319B (zh) 2016-09-09 2022-07-21 美商英塞特公司 吡唑并吡啶化合物及其用途
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018060072A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
AU2018242623B2 (en) 2017-03-31 2024-05-02 Aurigene Oncology Limited Compounds and compositions for treating hematological disorders
WO2018200786A1 (en) * 2017-04-26 2018-11-01 Yale University Compositions and methods for treating vitiligo
BR112020003292A2 (pt) 2017-08-16 2020-08-18 Vanderbilt University compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
WO2020002280A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
CN116640118B (zh) 2018-06-27 2025-12-19 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
CN119161323A (zh) 2018-06-27 2024-12-20 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型吡啶和吡嗪化合物
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
CN112513027B (zh) * 2018-08-17 2024-03-29 浙江海正药业股份有限公司 吲唑胺类衍生物及其制备方法和其在医药上的用途
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
EP3889150A4 (en) * 2018-12-25 2022-02-23 Shanghai Meiyue Biotech Development Co., Ltd. COMPOUND SERVING AS IRAQ INHIBITOR
CN111362920B (zh) * 2018-12-25 2024-06-07 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN111560012B (zh) * 2019-02-14 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111793064B (zh) * 2019-04-02 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
WO2020259626A1 (zh) * 2019-06-26 2020-12-30 南京明德新药研发有限公司 作为irak4抑制剂的咪唑并吡啶类化合物
UY38765A (es) * 2019-06-27 2021-01-29 Biogen Ma Inc Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
EP3997081A1 (en) 2019-07-11 2022-05-18 Escape Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
PE20221419A1 (es) 2019-08-06 2022-09-20 Incyte Corp Formas solidas de un inhibidor de hpk1
TWI832010B (zh) * 2019-09-24 2024-02-11 大陸商上海美悦生物科技發展有限公司 Irak抑制劑及其製備方法和用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
EP4319750A4 (en) 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN113278017B (zh) * 2021-05-27 2023-03-28 上海应用技术大学 取代吲唑类化合物、制备方法、应用和包含其的组合物
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
JP2024525580A (ja) * 2021-07-07 2024-07-12 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
CN118302425A (zh) * 2021-12-03 2024-07-05 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途
EP4613748A1 (en) 2022-11-04 2025-09-10 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Irak4 degradation agent and use thereof
JP2025538376A (ja) * 2022-11-17 2025-11-28 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 疼痛および炎症の制御のための方法および組成物
CN116120283B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种氘代啶酰胺类irak-4抑制剂药物及用途
KR20250004525A (ko) * 2023-06-29 2025-01-08 동화약품주식회사 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (es) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos.
WO2004013102A1 (de) * 2002-07-31 2004-02-12 Schering Aktiengesellschaft Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyrimidene
ATE500216T1 (de) 2003-06-25 2011-03-15 Je Il Pharmaceutical Co Ltd Tricyclische derivate oder pharmazeutisch unnbedenkliche salze davon, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
CA2591332A1 (en) 2004-12-08 2006-06-15 Warner-Lambert Company Llc Methylene inhibitors of matrix metalloproteinase
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
CA2641884A1 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
TWI435863B (zh) 2006-03-20 2014-05-01 Nihon Nohyaku Co Ltd Ｎ-２-（雜）芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑
EP2045253A4 (en) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
MX2009002377A (es) * 2006-09-07 2009-03-13 Biogen Idec Inc Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
WO2012061926A1 (en) 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
BR112013015460B1 (pt) * 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
CN103402985A (zh) 2011-02-10 2013-11-20 先正达参股股份有限公司 杀微生物的吡唑衍生物
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
AU2012217616B2 (en) 2011-02-18 2017-03-02 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
ES2591129T3 (es) 2012-05-21 2016-11-25 Bayer Pharma Aktiengesellschaft Tienopirimidinas
JP2015002717A (ja) 2013-06-21 2015-01-08 住友ベークライト株式会社 蓋付き容器
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10160753B2 (en) * 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
AU2015275730A1 (en) 2014-06-20 2016-12-15 Aurigene Discovery Technologies Limited Substituted indazole compounds as IRAK4 inhibitors
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
HK1249509A1 (zh) 2015-07-15 2018-11-02 Aurigene Discovery Technologies Limited 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109071489B (zh) 2016-04-29 2020-07-10 拜耳医药股份有限公司 吲唑的合成
HUE049331T2 (hu) 2016-04-29 2020-09-28 Bayer Pharma AG Indazolok szintézise
AU2017273771B2 (en) 2016-06-01 2022-09-29 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных

Also Published As

Publication number Publication date
WO2016083433A1 (de) 2016-06-02
RS60284B1 (sr) 2020-06-30
IL267537A (en) 2019-08-29
US20230174508A1 (en) 2023-06-08
RS65327B1 (sr) 2024-04-30
JP6496823B2 (ja) 2019-04-10
HUE049341T2 (hu) 2020-09-28
DK3674298T3 (da) 2024-04-08
EA032509B1 (ru) 2019-06-28
IL267537B (en) 2020-07-30
IL252185A0 (en) 2017-07-31
CN110305109B (zh) 2022-04-08
EP3674298B9 (de) 2024-06-19
TW202002973A (zh) 2020-01-16
KR20170085590A (ko) 2017-07-24
NI201700063A (es) 2017-07-17
PL3674298T3 (pl) 2024-06-24
SI3674298T1 (sl) 2024-05-31
CO2017005374A2 (es) 2017-08-31
CA2968614C (en) 2019-10-29
PT3224254T (pt) 2020-06-17
CY1123815T1 (el) 2022-03-24
IL252185B (en) 2019-10-31
BR112017011005A2 (pt) 2019-05-14
CN110305109A (zh) 2019-10-08
EP4260909A2 (de) 2023-10-18
MA41011B1 (fr) 2020-08-31
ME03745B (me) 2021-04-20
CN107406416B (zh) 2020-04-21
HRP20200974T1 (hr) 2020-10-02
CU20170073A7 (es) 2017-10-05
ES2976932T9 (es) 2024-09-05
IL269444B (en) 2020-07-30
PT3674298T (pt) 2024-04-01
CL2017001364A1 (es) 2017-12-15
KR102083857B1 (ko) 2020-03-03
SG10201903474PA (en) 2019-05-30
TWI717061B (zh) 2021-01-21
AR102827A1 (es) 2017-03-29
TWI689502B (zh) 2020-04-01
JO3705B1 (ar) 2021-01-31
PE20171376A1 (es) 2017-09-15
PH12017500972A1 (en) 2017-12-18
TN2017000226A1 (en) 2018-10-19
AU2015352603B2 (en) 2020-04-02
SI3224254T1 (sl) 2020-07-31
AU2015352603A1 (en) 2017-06-01
MX2017006910A (es) 2017-08-15
CU24448B1 (es) 2019-10-04
EP3224254B1 (de) 2020-04-15
ES2976932T3 (es) 2024-08-13
HRP20240414T1 (hr) 2024-06-21
ES2796285T3 (es) 2020-11-26
NZ732126A (en) 2018-09-28
MX380150B (es) 2025-03-12
AU2020200979B2 (en) 2021-01-07
BR122021002613B1 (pt) 2023-04-11
US20220388982A1 (en) 2022-12-08
LT3224254T (lt) 2020-06-10
MX2020010623A (es) 2022-02-16
SG10201903475TA (en) 2019-05-30
US10793545B2 (en) 2020-10-06
US12006303B2 (en) 2024-06-11
US12559473B2 (en) 2026-02-24
CN107406416A (zh) 2017-11-28
JP2017535585A (ja) 2017-11-30
IL269444A (en) 2019-11-28
UY36411A (es) 2016-06-30
US20250034111A1 (en) 2025-01-30
EP3224254A1 (de) 2017-10-04
EA201791137A1 (ru) 2017-11-30
UA120948C2 (uk) 2020-03-10
ECSP17032530A (es) 2017-06-30
EP4260909A3 (de) 2024-03-20
FI3674298T3 (fi) 2024-04-17
EP3674298B1 (de) 2024-01-10
US20190233395A1 (en) 2019-08-01
UA123813C2 (uk) 2021-06-02
US10308634B2 (en) 2019-06-04
AU2020200979A1 (en) 2020-02-27
LT3674298T (lt) 2024-04-10
BR112017011005B1 (pt) 2023-03-14
MX390119B (es) 2025-03-20
DK3224254T3 (da) 2020-07-13
DOP2017000127A (es) 2017-07-31
US12006304B2 (en) 2024-06-11
EP3674298A1 (de) 2020-07-01
CR20170220A (es) 2017-10-31
US20210053941A1 (en) 2021-02-25
US20170349570A1 (en) 2017-12-07
HUE065938T2 (hu) 2024-06-28
SG11201704092YA (en) 2017-06-29
CA2968614A1 (en) 2016-06-02
TW201629037A (zh) 2016-08-16

Similar Documents

Publication Publication Date Title
HUE065938T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
IL263709A (en) Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
IL251302A0 (en) History of boronic acid, their preparation and medicines containing them
IL251300A0 (en) History of boronic acid, their preparation and medicines containing them
IL247239A0 (en) Complexes of sirolimus and its derivatives, a process for their preparation and pharmaceutical preparations containing them
IL251299A0 (en) History of boronic acid, their preparation and medicines containing them
IL251301A0 (en) History of boronic acid, their preparation and medicines containing them
IL250267A0 (en) History of indolizine, their preparation and pharmaceutical preparations containing them
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
IL249308A0 (en) The history of quinoline, their preparation and pharmaceutical preparations containing them
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
IL258977B (en) Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them
LT2957280T (lt) Kieta farmacinė citizino kompozicija ir jos gamybos būdas
IL267279A (en) Pharmaceutical formulations of suvorexant
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
PT3390403T (pt) Composição farmacêutica compreendendo derivados de indole, processo para preparação e uso dos mesmos
PL2996675T3 (pl) Formulacja farmaceutyczna, sposób wytwarzania formulacji farmaceutycznej i roztwór do infuzji oraz ich zastosowanie jako wyrobu medycznego i/lub leku
HK1233982A1 (en) Drug delivery device for the delivery of two medicaments
HUP1400084A2 (hu) Dabigatran és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói